

**Versican Antibody**  
**Versican Antibody, Clone S351-23**  
**Catalog # ASM10273****Specification**

---

**Versican Antibody - Product Information**

Application	<b>WB, ICC</b>
Primary Accession	<a href="#">O62059</a>
Other Accession	<a href="#">AAH96495</a>
Host	<b>Mouse</b>
Isotype	<b>IgG1</b>
Reactivity	<b>Human, Mouse, Rat</b>
Clonality	<b>Monoclonal</b>

**Description**

Mouse Anti-Mouse Versican Monoclonal IgG1

**Target/Specificity**

Detects &gt;350kDa.

**Other Names**

Chondroitin sulfate proteoglycan 2 Antibody, CSPG2 Antibody, ERVR Antibody, GHAP Antibody, PG-M Antibody, VCAN Antibody, Chondroitin sulfate proteoglycan 2 Antibody, Chondroitin sulfate proteoglycan core protein 2 Antibody, Glial hyaluronate binding protein Antibody, Glial hyaluronate-binding protein Antibody, Large fibroblast proteoglycan Antibody, Large fibroblast proteoglycan Antibody, PGM Antibody, V1 Neo Antibody, Versican core protein Antibody, Versican proteoglycan Antibody, Versican V0 Antibody, WGN 1 Antibody, WGN Antibody, WGN1 Antibody

**Immunogen**

Fusion protein amino acids 362-585 (glycosaminoglycan alpha domain) of mouse Versican core protein

**Purification**

Protein G Purified

Storage **-20°C****Storage Buffer**

PBS pH7.4, 50% glycerol, 0.1% sodium azide

Shipping Temperature **Blue Ice or 4°C****Certificate of Analysis**

1 µg/ml of SMC-439 was sufficient for detection of Versican in 20 µg of mouse brain membrane lysate and assayed by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.

**Cellular Localization**


Extracellular Space | Extracellular Matrix

**Versican Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Versican Antibody - Images



Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-Versican Monoclonal Antibody, Clone N351/23 (ASM10273). Tissue: Neuroblastoma cells (SH-SY5Y). Species: Human. Fixation: 4% PFA for 15 min. Primary Antibody: Mouse Anti-Versican Monoclonal Antibody (ASM10273) at 1:200 for overnight at 4°C with slow rocking. Secondary Antibody: AlexaFluor 488 at 1:1000 for 1 hour at RT. Counterstain: Phalloidin-iFluor 647 (red) F-Actin stain; Hoechst (blue) nuclear stain at 1:800, 1.6mM for 20 min at RT. (A) Hoechst (blue) nuclear stain. (B) Phalloidin-iFluor 647 (red) F-Actin stain. (C) Versican Antibody (D) Composite.

### Versican Antibody - Background

Versican (chondroitin sulfate proteoglycan 2) is a large extracellular matrix proteoglycan involved in cell growth and differentiation. Important as a structural molecule, versican creates loose and hydrated matrices during key events in development and disease. The protein contains hyaluronic acid and glycosaminoglycan-binding domains, epidermal growth factor-like repeats, a Lectinlike sequence and a complement regulatory protein-like domain. Splice variants differ greatly in length and degree of modification by glycoaminoglycan chains. Accumulation around smooth muscle cells in lesions of atherosclerosis suggests a role for versican in atherogenesis. Versican, differentially expressed in human melanoma, plays a role in tumor development and may be a reliable marker for clinical diagnosis. The organization of HA- and versican-rich pericellular matrices may facilitate migration and mitosis by diminishing cell surface adhesivity and affecting cell shape through steric exclusion and the viscous properties of HA proteoglycan gels.

### Versican Antibody - References

1. Dours-Zimmermann M.T. and Zimmermann D.R. (1994) J. Biol. Chem. 52: 32992-32998.
2. Evanko S.P., Angello J.C. and Wight T.N. (1999) Arterioscler. Thromb. Vasc. Biol. 4:1004-1013.
3. Lemire J.M., et al. (1999) Arterioscler. Thromb. Vasc. Biol. 7: 1630-1639.

4. Wight T.N. (2002) *Curr. Opin. Cell Biol.* 5: 617-623.

5. Touab M., Villena J., Barranco C., Arumi-Uria M. and Bassols A. (2002) *Am. J. Pathol.* 2: 549-557.